智通财经APP获悉，德银发布研报称，翰森制药(03692)2024财年纯利超预期，营业额符预期，毛利率改善。维持“买入”评级，并将目标价由22港元调高至24.7港元。该行指，公司已成功转型为以创新药物为重心的公司，并透过持续向全球领先制药公司外授其管线资产，证明其研发能力。在推出下一波创新资产前，现有产品组合应可支持公司未来两年的增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.